Reduction in the presence of cryoglobulins over time in the hemodialysis treatment

Figures & data

Table 1. Size of cryoprecipitates: Quantification, by observational criteria, of the presence of cryoprecipitate in the serum of patients with chronic kidney disease on hemodialysis (HD).

Patient	Time on HD (days)	1st Sampling	30 days	60 days	90 days	120 days
1	7	+ + + +	+ + + +	+ + +	+ +	Transplanted
2	15	+ + + +	+ + +	+	Died	- - - -
3	25	+ +	+ +	+	+	+
4	30	+ + + +	+ +	+ +	Transferred	- - - -
5	30	+ + +	+ +	+ +	+ + +	+
6	41	+ +	+ +	+ +	+ +	+ +
7	55	+ + + +	+	+	+	+
8	54	+	+	Negative	Transferred	- - - -
9	60	+ + + +	+	+	+	+
10	67	+ + +	+ +	+ + +	+ +	+ + +
11	80	+	Negative	Negative	+	Negative
12	87	+	- - - -	+	+	- - - -
13	120	+	+	+	+	+
14	124	+	Negative	+	Negative	Transplanted

Data obtained from a first sampling and 30, 60, 90 and 120 days afterwards. Qualification of the cryoprecipitate: + (smaller in size); ++++ (larger in size); - - - -: no material for analysis; negative: without cryoprecipitate formation.

Table 2. Quantification of cryoprecipitate: Concentration levels (mg/dL) of components formed in the serum of patients with chronic kidney disease on dialysis: data from initial and final sample measurements.

	Initial					Final
Patient	IgM	IgA	IgG	C3	C4	IgM	IgA	IgG	C3	C4
1	19.1	129.8	662.6	79.3	26.5	3.4	83.5	235.3	51.8	10.8
2	122.3	509.9	1810.9	143.1	63.1	3.4	42.1	86.5	9.5	2.1
3	3.5	12.5	121.5	9.5	2.1	3.4	12.5	86.5	9.5	2.1
4	41.0	58.1	435.3	31.8	10.8	32.0	34.4	232.0	27.1	2.1
5	3.6	92.4	310.5	41.5	14.9	3.4	12.5	121.5	9.5	3.7
6	3.5	12.5	194.2	9.5	2.1	3.4	12.5	121.5	9.5	2.1
7	23.4	83.5	392.6	36.6	9.8	3.4	12.5	86.5	9.5	2.1
8	3.4	12.5	86.5	9.5	2.1	3.4	12.5	86.5	9.5	2.1
9	19.1	129.8	662.6	79.3	26.5	3.4	83.5	235.3	51.8	10.8
10	19.1	74.8	310.5	27.1	5.3	19.1	120.2	87.5	36.6	5.3
11	3.4	12.5	86.5	9.5	2.1	3.4	12.5	86.5	9.5	2.1
12	3.4	12.5	86.5	9.5	2.1	3.4	12.5	86.5	9.5	2.1
13	3.4	42.1	232.0	9.5	2.1	3.4	12.5	86.5	9.5	2.1
14	3.4	12.5	86.5	9.5	2.1	3.4	12.5	86.5	9.5	2.1

Table 3. Statistical analysis: Comparison of the results from the quantification (mg/dL) of the components of the cryoprecipitate formed in the beginning and at the end of the study.

	IgM	IgA	IgG	C3	C4
Mean - Initial ± SD	19.4 ± 31.8	85.4 ± 129.7	391.3 ± 454.6	36.1 ± 39.5	12.3 ± 17.0
Mean - Final ± SD	6.6 ± 8.4	34.0 ± 35.7	123.2 ± 61.4	18.7 ± 16.2	3.7 ± 3.1
95% CI - Initial	1.07–37.73	10.48–160.29	128.88–653.79	13.29–58.88	2.42–22.10
95% CI - Final	1.69–11.43	13.41–54.62	87.76–158.68	9.36–28.11	1.87–5.54
p value	.012	.035	.005	.042	.027

Mean, ± standard deviation (SD) and 95% confidence interval (CI) of concentration values results from initial and final measurements. p values for the comparison of initial and final parameters, according to the Wilcoxon test.